Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients
A Single-arm Open-label Safety Study of SMOFlipid to Evaluate the Risk of Developing Essential Fatty Acid Deficiency (EFAD) and/or Parenteral Nutrition-associated Cholestasis (PNAC) in Pediatric Patients 1 Month to 17 Years of Age and in Adult Patients, Who Are Anticipated to Need 8 Weeks or Longer of Parenteral Nutrition Treatment
Fresenius Kabi
100 participants
Oct 28, 2024
INTERVENTIONAL
Conditions
Summary
Evaluate the risk of developing EFAD and/or PNAC in adult and pediatric patients 1 month of age and older, who are anticipated to need 8 weeks or longer of parenteral nutrition treatment with SMOFlipid.
Eligibility
Inclusion Criteria5
- Age Limits: and Adults
- Male or female patients, at least 1 month of age.
- Patients who require PN for at least 5 days/week.
- Patients who receive 80% or more of their total energy requirements as PN at enrollment and who are expected to receive 80% or more of their total energy requirements as PN for at least 56 days.
- Written informed consent. In case of pediatric patients, informed consent must be obtained from parent(s) or legal representatives. If possible, the assent of the pediatric patient must also be obtained (according to local law).
Exclusion Criteria17
- Use of any other lipid injectable emulsion than SMOFlipid within 6 months prior to study participation
- Known hypersensitivity to fish, egg, soybean, or peanut proteins, or to any of the active ingredients or excipients of SMOFlipid.
- Hyperlipidemia or disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride concentration \>250 mg/dL in infants or \>400 mg/dL in older pediatric and adult patients).
- Inborn errors of amino acid metabolism.
- Cardiopulmonary instability (including pulmonary edema, cardiac insufficiency, myocardial infarction, acidosis and hemodynamic instability requiring significant vasopressor support).
- Hemophagocytic syndrome.
- Liver enzymes (either AST, or ALT, or GGT) exceeding 2 x upper limit of normal range
- Direct bilirubin exceeding 2 x upper limit of normal range
- INR exceeding 2 x upper limit of normal range and patient not receiving oral anticoagulants.
- Any known hepatic condition outside of IFALD that will increase direct bilirubin ≥2.0 mg/dL.
- Clinically significant abnormal levels of any serum electrolyte (sodium, potassium, magnesium, calcium, chloride, phosphate).
- Active bloodstream infection demonstrated by positive blood culture at screening.
- Severe renal failure (eGFR \<15 ml/min per 1.73 m2) including patients on renal replacement therapy.
- Abnormal blood pH, oxygen saturation, or carbon dioxide.
- Pregnancy or lactation.
- Participation in another interventional clinical study.
- Unlikely to survive longer than 56 days.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
SMOFlipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of SMOFlipid is 0.20 g/mL, and comprises a mixture of soybean oil, MCT, olive oil, and fish oil. SMOFlipid belongs to the pharmacotherapeutic group: "Solutions for parenteral nutrition, fat emulsions" (ATC-code: B05BA02). SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06049680